The effect of chitosan nanospheres on the immunogenicity of Toxoplasma lysate vaccine in mice.
Toxoplasmosis, a zoonotic parasitic disease, is a huge challenge for which there is no effective vaccine up till now. In this study, chitosan nanospheres encapsulated with Toxoplasma lysate vaccine was evaluated for its ability to protect mice against both acute and chronic toxoplasmosis models of infection. Results showed that chitosan nanospheres were equally effective to Freund's incomplete adjuvant (FIA) in enhancing the efficacy of Toxoplasma lysate vaccine. The effectiveness was demonstrated by the delayed death of vaccinated mice following challenge either with virulent RH or avirulent Me49 strains, the significant decrease in parasite density in different organs, significant increase in the humoral and cellular immune response (IgG and IFN γ) with a marked reduction of pathological changes in the different organs. However chitosan nanospheres were superior to FIA due to their cost effective preparation and much less necrotic changes induced in the studied organs. The success of chitosan polymer as an alternative to commonly used adjuvants paves the way for the use of other newly developed polymers to be used in the field of vaccine development.
Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Mona M
MM
El Temsahy
Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Eman D H
ED
El Kerdany
Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Maha M
MM
Eissa
Department of Biophysics and Biomedics, Medical Research Institute, University of Alexandria, Alexandria, Egypt.
Thanaa I
TI
Shalaby
Department of Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Iman M
IM
Talaat
Department of Medical Parasitology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Nermine M F H
NM
Mogahed
Avirulent Me49 Toxoplasma strain; Crude Toxoplasma lysate vaccine; Encapsulated chitosan nanospheres; Virulent RH Toxoplasma strain